Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.30 |
| ▸ | TLR4 | O00206 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | NEK3 | P51956 | 1/20 | 0.30 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
| ▸ | NEK5 | Q6P3R8 | 1/20 | 0.30 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974599 | 0.88 | DRD2 (0.36) | DRD2DRD3DRD4STK17ATLR4 | |
| SCHEMBL24974581 | 0.81 | CRBN (0.34) | — | |
| SCHEMBL21151335 | 0.77 | LIPG (0.32) | DRD2DRD3DRD4 | |
| SCHEMBL21150938 | 0.77 | DRD2 (0.34) | DRD2DRD3DRD4 | |
| SCHEMBL21150845 | 0.75 | NAMPT (0.34) | LIMK1 | |
| SCHEMBL21151259 | 0.73 | NAMPT (0.34) | — | |
| SCHEMBL21151783 | 0.73 | NAMPT (0.33) | LIMK1 | |
| SCHEMBL21150858 | 0.73 | NAMPT (0.36) | — | |
| SCHEMBL21151136 | 0.72 | HDAC1 (0.33) | DRD2DRD3 | |
| SCHEMBL21151158 | 0.72 | NAMPT (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | DRD2 1684/4885DRD3 2019/4885DRD4 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.